Race Receives $228k R&D Tax Incentive Refund
Filed with ASX · · 1 page · English
Earlier from Racura Oncology
- Race appoints leading haematologist to support Bisantrene
- Race signs agreement for Bisantrene NPP in Israel
- Race appoints Biosynergy to pursue Bisantrene licensing
- September 2018 Quarterly Report
- Appendix 4E & Financial Statements
Later from Racura Oncology
- Principal Investigator appointed for Bisantrene
- Race files Bisantrene IND with FDA
- Bisantrene IND Update
- Bisantrene AML trial to start in Israel
- First patient treated in Bisantrene trial in Israel
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology